13 Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 13 from our risk checks.
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£34.65 |
| 52 Week High | UK£35.20 |
| 52 Week Low | UK£17.44 |
| Beta | 0.65 |
| 1 Month Change | 19.69% |
| 3 Month Change | 57.86% |
| 1 Year Change | 58.22% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 13 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 8.6% | 3.5% | 4.6% |
| 1Y | 58.2% | -5.3% | -1.1% |
Return vs Industry: 13 exceeded the Hong Kong Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 13 exceeded the Hong Kong Market which returned -1.1% over the past year.
Price Volatility
| 13 volatility | |
|---|---|
| 13 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 15.2% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 13's share price has been volatile over the past 3 months.
Volatility Over Time: 13's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,988 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
HUTCHMED (China) Limited Fundamentals Summary
| 13 fundamental statistics | |
|---|---|
| Market cap | HK$29.41b |
| Earnings (TTM) | HK$787.57m |
| Revenue (TTM) | HK$6.55b |
37.3x
P/E Ratio4.5x
P/S RatioIs 13 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 13 income statement (TTM) | |
|---|---|
| Revenue | US$838.00m |
| Cost of Revenue | US$686.45m |
| Gross Profit | US$151.55m |
| Other Expenses | US$50.77m |
| Earnings | US$100.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 18.08% |
| Net Profit Margin | 12.03% |
| Debt/Equity Ratio | 10.7% |
How did 13 perform over the long term?
See historical performance and comparison